Аннотация
Меланома относится к опухолям, характеризующимся ранним метастазированием и высокой смертностью пациентов. Резистентность клеток меланомы и отсутствие эффективных терапевтических методов существенно осложняют ее лечение. Одним из потенциальных маркеров, указывающих на ее клинические проявления, в частности прогрессирование и развитие отдаленных метастазов, является белок с меланома-ингибирующей активностью MIA (Melanoma
Inhibitory Activity protein). Открытие и изучение механизма действия этого белка были проведены при исследовании меланомы, что предопределило направление последующих работ по оценке его влияния на развитие и течение именно данного заболевания. В данном обзоре приводится информация о структуре и функциях белка MIA, его использовании в качестве диагностической мишени меланомы и индикатора терапевтического ответа на некоторые препараты, применяемые для лечения меланомы. В настоящее время стали появляться работы, в которых уровень MIA оценивают и
при других заболеваниях, так, в обзоре представлены данные пока немногочисленных исследований о взаимосвязи MIA с
другими типами рака и неонкологическими заболеваниями. Несмотря на очевидную перспективность использования белка MIA в качестве онкомаркера меланомы, значение рекомендованного порогового уровня MIA в сыворотке является пока
предметом дискуссии, но при этом MIA может быть удобным инструментом для оценки клинических проявлений меланомы и объектом интереса для создания препаратов, направленных на ингибирование его функции в опухолевых клетках.
Поисковая работа была проведена с использованием международных научных баз данных PubMed, ScienceDirect, Scopus,
Elsevier, а также библиотек elibrary.ru
Annotation
Melanoma is a kind of tumor characterized by early metastasis and high patient mortality rates. The resistance of melanoma cells
and the lack of effective therapeutic methods significantly complicate its treatment. One of the potential markers capable of revealing melanoma clinical manifestations (in particular, the progression and development of distant metastases) is the protein with
melanoma inhibitory activity MIA (Melanoma Inhibitory Activity protein). This protein discovery and study was made while studying
melanoma, which predetermined the direction of subsequent researches to assess its effect on the development and course of this
disease. This review provides information on the structural and functional features of this protein, its use as a diagnostic target for
melanoma and as indicator of therapeutic response to several drugs used to treat melanoma. Currently, studies are appearing in
which the level of MIA is assessed in other diseases, so the review presents data of the yet few studies on the relationship between
MIA and other types of cancer and non-cancer diseases. Despite the obvious promise of using the MIA protein as a tumor marker for
melanoma, the value of the recommended cut-off level of MIA in serum is still a subject of debate. At the same time, MIA can be a
convenient tool for assessing the clinical manifestations of melanoma and an object of interest for the creation of drugs to inhibit its
function in tumor cells.
The work was carried out using international scientific databases PubMed, ScienceDirect, Scopus, Elsevier, as well as elibrary.ru.
Key words: review; melanoma; melanoma inhibitory activity (MIA); melanoma diagnosis
Список литературы
1. Malishevskaya N.P., Sokolova A.V., Demidov L.V. The incidence of skin melanoma in the Russian Federation and federal districts. Meditsinskiy sovet. 2018; (10):161-5. DOI: 10.21518/2079-701X-2018-10- 161-165. (in Russian)
2. Pleshkan V.V., Zinovyeva M.V., Sverdlov E.D. Melanoma: Surface markers as the first point of targeted delivery of therapeutic genes in multilevel gene therapy. Mol. Biol. (Mosk). 2011; 45: 375-91. DOI:10.1134/S0026893311030149.
3. Bogdahn U., Apfel R., Hahn M., Gerlach M., Behl C., Hoppe J. et. al. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res. 1989; 49 (19): 5358-63.
4. Palmer S.R., Erickson L.A., Ichetovkin I., Knauer D.J., Markovic S.N. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin. Proc. 2011. 86 (10): 981-90. DOI: 10.4065/mcp.2011.0287.
5. Bosserhoff A.K., Kaufmann M., Kaluza B., Bartke I., Zirngibl H., Hein R. et. al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997; 57(15): 3149-53.
6. Bosserhoff A.K., Lederer M., Kaufmann M., Hein R., Stolz W., Apfel R. et. al. MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res. 1999; 19(4A): 2691-3.
7. Bosserhoff A.K., Dreau D., Hein R., Landthaler M., Holder W.D., Buettner R. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Recent Results Cancer Res. 2001; 158(158): 158-68. DOI: 10.1007/978-3-642-59537-0_16.
8. Riechers A., Bosserhoff A.K. Melanoma inhibitory activity in melanoma diagnostics and therapy — a small protein is looming large. Exp. Dermatol. 2014; 23(1): 12-4. DOI: 10.1111/exd.12281.
9. Pleshkan V.V., Alekseenko I.V., Zinovyeva M.V., Vinogradova T.V., Sverdlov E.D. Promoters with cancer cell-specific activity for melanoma gene therapy. Acta Naturae. 2011; 3(2):13-21.
10. Tscheudschilsuren G., Bosserhoff A.K., Schlegel J., Vollmer D., Anton A., Alt V. et.al. Regulation of mesenchymal stem cell and chondrocyte differentiation by MIA. Exp. Cell Res. 2006; 312(1): 63-72. DOI: 10.1016/j.yexcr.2005.09.017.
11. Shen J., Amari N., Zack R., Skrinak R.T., Unger T.L., Posavi M. et.al. Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson’s Disease. Ann. Neurol. 2022; 92(2): 255-69. DOI: 10.1002/ ana.26410.
12. Müller-Ladner U., Bosserhoff A.K., Dreher K., Hein R., Neidhart M., Gay S. et.al. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford). 1999; 38(2): 148-54. DOI: 10.1093/rheumatology/38.2.148.
13. Yeremenko N., Härle P., Cantaert T., van Tok M., van Duivenvoorde L.M., Bosserhoff A. et.al. The cartilage protein melanoma inhibitory activity contributes to inflammatory arthritis. Rheumatology (Oxford). 2014; 53(3): 438-47. DOI: 10.1093/rheumatology/ket382.
14. Sasahira T., Kirita T., Nishiguchi Y., Kurihara M., Nakashima C., Bosserhoff A.K. et.al. A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma. Oncotarget. 2016; 7(21): 31137-52. DOI: 10.18632/oncotarget.9082.
15. Lougheed J.C., Holton J.M., Alber T., Bazan J.F., Handel T.M. Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. Proc. Natl. Acad. Sci. USA. 2001; 98(10): 5515-20. DOI: 10.1073/pnas.091601698.
16. Bosserhoff A.K. Role of melanoma inhibitory activity in early development of malign chapter. In: Vincent J. Hearing, Stanley P. L. Leong, eds. From melanocytes to melanoma. The progression to malignancy. Humana Press; 2006: 475 – 87.
17. Stoll R., Renner C., Buettner R., Voelter W., Bosserhoff A.K., Holak T.A. Backbone dynamics of the human MIA protein studied by 15N NMR relaxation: Implications for extended interactions of SH3 domains. Protein Sci. 2003; 12(3): 510-9. DOI: 10.1110/ps.0222603.
18. Stoll R., Renner C., Zweckstetter M., Brüggert M., Ambrosius D., Palme S. et.al. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J. 2001; 20(3): 340-9. DOI: 10.1093/emboj/20.3.340.
19. Blesch A., Bosserhoff A.K., Apfel R., Behl C., Hessdoerfer B., Schmitt A. et. al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994; 54(21): 5695-5701.
20. Bosserhoff A.K., Buettner R. Establishing the protein MIA (melanoma inhibitory activity) as a marker for chondrocyte differentiation. Biomaterials. 2003; 24(19): 3229-34. DOI: 10.1016/s0142-9612(03)00184-4.
21. Koehler M.R., Bosserhoff A., von Beust G., Bauer A., Blesch A., Buettner R. et.al. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics. 1996; 35(1): 265-7. DOI: 10.1006/geno.1996.0352.
22. Bosserhoff A.K., Hein R., Bogdahn U., Buettner R. Structure and Promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J. Biol. Chem. 1996; 271(1): 490-5. DOI: 10.1074/jbc.271.1.490.
23. Schmidt J., Riechers A., Stoll R., Amann T., Fink F., Spruss T. et.al. Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition. PLoS One. 2012; 7(5): e37941. DOI: 10.1371/journal.pone.0037941.
24. Bauer R., Humphries M., Fässler R., Winklmeier A., Craig S.E., Bosserhoff A.K. Regulation of integrin activity by MIA. J. Biol. Chem. 2006; 281(17): 11669- 77. DOI: 10.1074/jbc.M511367200.
25. Jachimczak P., Apfel R., Bosserhoff A.K., Fabel K., Hau P., Tschertner I. et.al. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int. J. Cancer. 2005; 113(1): 88-92. DOI: 10.1002/ijc.20549/.
26. Bordignon M., Luisetto R., Valente M.L., Fedrigo M., Castellani C., Angelini A. et.al. Melanoma Inhibitory Activity (MIA) is able to induce vitiligo-like depigmentation in an in vivo mouse model by direct injection in the tail. Front. Med. (Lausanne). 2020; 7:430. DOI: 10.3389/fmed.2020.00430.
27. Yip K.T., Zhong X.Y., Seibel N., Pütz S., Autzen J., Gasper R. et.al. Small molecules antagonise the MIA-fibronectin interaction in malignant melanoma. Sci. Rep. 2016; 6: 25119. DOI: 10.1038/srep25119.
28. Bosserhoff A.K., König B., Riechers A., Schmidt J. Peptides or antibodies which bind to melanoma inhibitory activity (MIA) protein. Patent WO2011113604A1. 2011 Sept 22.
29. Bashmakova E.E., Panamarev N.S., Kudryavtsev A.N., Frank L.A. N-extended photoprotein obelin to competitively detect small protein tumor markers. Biochem. Biophys. Res. Commun. 2022; 598: 69-73. DOI: 10.1016/j.bbrc.2022.02.011.
30. Hofmann M.A., Gussmann F., Fritsche A., Biesold S., Schicke B., Küchler I. et.al. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res. 2009; 19(1): 17-23. DOI: 10.1097/
CMR.0b013e32831bc78c.
31. Hofmann M.A., Schicke B., Fritsch A., Biesold S., Gussmann F., Küchler I. et.al. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. J. Dermatol. 2011; 38(9): 880-6. DOI: 10.1111/j.1346-8138.2011.01219.x.
32. Nikolin B., Djan I., Trifunovic J., Dugandzija T., Novkovic D., Djan V. et.al. MIA, S100 and LDH as important predictors of overall survival of patients with stage IIb and IIc melanoma. J. BUON. 2016; 21(3): 691-7.
33. Díaz-Lagares A., Alegre E., Arroyo A., González-Cao M., Zudaire M.E., Viteri S.et.al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011; 32(6): 1155-61. DOI: 10.1007/s13277-011-0218-x.
34. Li C., Liu J., Jiang L., Xu J., Ren A., Lin Y. et.al. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population. Medicine (Baltimore). 2021; 100(8): e24840. DOI: 10.1097/MD.0000000000024840.
35. Alegre E., Zubiri L., Perez-Gracia J.L., González-Cao M., Soria L., Martín-Algarra S. et.al. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clin. Chim. Acta. 2016; 454: 28-32. DOI: 10.1016/j.cca.2015.12.031.
36. Sandru A., Panaitescu E., Voinea S., Bolovan M., Stanciu A., Cinca S. et.al. Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. J. Skin. Cancer. 2014; 2014: 843214. DOI: 10.1155/2014/843214.
37. Vucetiс B., Rogan S.A., Hrabac P., Hudoroviс N., Cupic H., Lukinac L. et.al. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res. 2008;18(3): 201-7. DOI: 10.1097/CMR.0b013e3283021929.
38. Datz E., Zeman F., Koller M., Szeimies R.M., Berneburg M., Landthaler M. et.al. Phototherapy-induced elevation of serum level of melanoma inhibitory activity. Photodermatol.Photoimmunol .Photomed. 2019; 35(4): 255- 60. DOI: 10.1111/phpp.12461.
39. Sanmamed M.F., Fernández-Landázuri S., Rodríguez C., Lozano M.D., Echeveste J.I., Pérez Gracia J.L. et.al. Relevance of MIA and
S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin. Chim. Acta. 2014; 429: 168-74. DOI: 10.1016/j.cca.2013.11.034.
40. Tan N., Venetsanakos E., Faure M., Heise C. Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma. Patent WO2008013912A1; 2008 Jan 31.
41. Uslu U., Schliep S., Schliep K., Erdmann M., Koch H.U., Parsch H. et.al. Comparison of the serum tumor markers S100 and melanomainhibitory activity (MIA) in the monitoring of patients with metastatic melanoma receiving vaccination immunotherapy with dendritic cells. Anticancer Res. 2017; 37(9): 5033-7. DOI: 10.21873/anticanres.11918.
42. Schmidt J., Riechers A., Bosserhoff A.K. MIA-a new target protein for malignant melanoma therapy. Histol. Histopathol. 2013; 28 (4): 421-6. DOI: 10.14670/HH-28.421.
43. Sasahira T., Bosserhoff A.K., Kirita T. The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer. Pathol Int. 2018; 68(5): 278- 286. DOI: 10.1111/pin.12672.
44. Hau P., Ruemmele P., Kunz-Schughart L.A., Doerfelt A., Hirschmann B., Lohmeier A. et.al. Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma. Oncol. Rep. 2004; 12(6): 1355-64. DOI: 10.3892/or.12.6.1355.
45. El Fitori J., Kleeff J., Giese N.A., Guweidhi A., Bosserhoff A.K., Büchler M.W. et.al. Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic ca